Literature DB >> 17342168

Aberrant extracellular signal-regulated kinase (ERK) 5 signaling in hippocampus of suicide subjects.

Yogesh Dwivedi1, Hooriyah S Rizavi, Tara Teppen, Nobuyuki Sasaki, Hu Chen, Hui Zhang, Rosalinda C Roberts, Robert R Conley, Ghanshyam N Pandey.   

Abstract

Extracellular signal-regulated kinase 5 (ERK5), the newest member of the mitogen-activated protein (MAP) kinase family, is regulated differently than the other MAP kinases. Emerging evidence suggest the role of ERK5 signaling in promoting cell proliferation, differentiation, neuronal survival, and neuroprotection. The present study investigates whether suicide brain is associated with alterations in components of the ERK5 signaling cascade. In the prefrontal cortex (PFC) and hippocampus of suicide subjects (n=28) and nonpsychiatric control subjects (n=21), we examined the catalytic activities and protein levels of ERK5 and upstream MAP kinase kinase MEK5 in various subcellular fractions; mRNA levels of ERK5 in total RNA; and DNA-binding activity of myocyte enhancer factor (MEF)2C, a substrate of ERK5. In the hippocampus of suicide subjects, we observed that catalytic activity of ERK5 was decreased in cytosolic and nuclear fractions, whereas catalytic activity of MEK5 was decreased in the total fraction. Further, decreased mRNA and protein levels of ERK5, but no change in protein level of MEK5 were noted. A decrease in MEF2C-DNA-binding activity in the nuclear fraction was also observed. No significant alterations were noted in the PFC of suicide subjects. The observed changes were not related to a specific psychiatric diagnosis. Our findings of reduced activation and/or expression of ERK5 and MEK5, and reduced MEF2C-DNA-binding activity demonstrate abnormalities in ERK5 signaling in hippocampus of suicide subjects and suggest possible involvement of this aberrant signaling in pathogenic mechanisms of suicide.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17342168     DOI: 10.1038/sj.npp.1301372

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  12 in total

Review 1.  Evidence demonstrating role of microRNAs in the etiopathology of major depression.

Authors:  Yogesh Dwivedi
Journal:  J Chem Neuroanat       Date:  2011-04-14       Impact factor: 3.052

2.  Formation of chimeric genes by copy-number variation as a mutational mechanism in schizophrenia.

Authors:  Caitlin Rippey; Tom Walsh; Suleyman Gulsuner; Matt Brodsky; Alex S Nord; Molly Gasperini; Sarah Pierce; Cailyn Spurrell; Bradley P Coe; Niklas Krumm; Ming K Lee; Jonathan Sebat; Jon M McClellan; Mary-Claire King
Journal:  Am J Hum Genet       Date:  2013-10-03       Impact factor: 11.025

3.  GABAergic control of depression-related brain states.

Authors:  Bernhard Luscher; Thomas Fuchs
Journal:  Adv Pharmacol       Date:  2015-01-14

4.  Role of ERK1, 2, and 5 in dopamine neuron survival during aging.

Authors:  Mayur S Parmar; Juliann D Jaumotte; Stephanie L Wyrostek; Michael J Zigmond; Jane E Cavanaugh
Journal:  Neurobiol Aging       Date:  2013-10-23       Impact factor: 4.673

Review 5.  The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression.

Authors:  Gabriele Masi; Paola Brovedani
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 6.  Kinase-mediated signaling cascades in mood disorders and antidepressant treatment.

Authors:  Li-Lian Yuan; Eric Wauson; Vanja Duric
Journal:  J Neurogenet       Date:  2016-10-27       Impact factor: 1.250

Review 7.  Cell atrophy and loss in depression: reversal by antidepressant treatment.

Authors:  Mounira Banasr; Jason M Dwyer; Ronald S Duman
Journal:  Curr Opin Cell Biol       Date:  2011-10-11       Impact factor: 8.382

Review 8.  Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression.

Authors:  Kristie T Ota; Ronald S Duman
Journal:  Neurobiol Dis       Date:  2012-06-09       Impact factor: 5.996

Review 9.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

10.  Future Antidepressant Targets: Neurotrophic Factors and Related Signaling Cascades.

Authors:  Heath D Schmidt; Mounira Banasr; Ronald S Duman
Journal:  Drug Discov Today Ther Strateg       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.